[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peanut-allergy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peanut-allergy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,52,82,107,144,172,198,224,242,265,288,315],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100642457","phase-1-safety-of-moon101-for-the-treatment-of-peanut-allergy-100642457",false,"NCT07580898","Safety of MOON101 for the Treatment of Peanut Allergy","SURVEYOR","Inclusion Criteria:\n\n1. Participant and\u002For parent\u002Fguardian must understand and provide written informed consent and assent.\n2. Aged 4 to 55 years per applicable enrolling group below of any sex\u002Frace\u002Fethnicity at informed consent and assent (if applicable) form signature:\n\n   1. Group 1: Adults; ages 18-55 years\n   2. Group 2: Adolescents; ages 12-17 years\n   3. Group 3: Children; ages 4-11 years\n3. A physician-confirmed medical history of peanut allergy within minutes to 2 hours of ingesting peanut.\n4. A peanut SPT with mean wheal diameter as defined by age.\n\nExclusion Criteria:\n\n1. Laboratory evidence of liver or renal disease.\n2. Poorly controlled or severe asthma\u002Fwheezing\n3. Previous use of any form of peanut allergen immunotherapy within the 6 months prior to Screening.\n4. Previous use of any biologic therapies such as omalizumab, dupilumab, benralizumab, reslizumab, tezepelumab, or any other immunomodulatory or immunosuppressive therapy (not including corticosteroids) within the 6 months prior to Screening.\n5. Current use of β-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), or calcium channel blockers.\n6. Treatment with a burst of oral, intramuscular (IM), intra-articular (IA), or intravenous (IV) steroids of more than two days within 30 days of Screening.\n7. Unable to temporarily discontinue antihistamines (5 half-lives of the antihistamine) prior to SPT.\n8. Unable to discontinue topical steroids to the testing application site for 24 hours prior to testing.\n\nOther inclusion\u002Fexclusion criteria apply.","ALL","4 Years","55 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this open-label, single escalating dose study in 3 sequential groups: adults, adolescents, and children with peanut allergy is to assess the safety of MOON101. The main question it aims to answer is:\n\n1. the incidence and frequency of all treatment emergent adverse events (TEAEs) from baseline through study exit.\n2. to determine the highest tolerated dose for each participant, as defined by the highest MOON101 dose level administered which did not cause a dose-limiting symptom (DLS).\n\nThe study will compare MOON101 and placebo. All participants will receive both active MOON101 (peanut allergen) and placebo (no peanut allergen).",[27],"Peanut Allergy",[29,30,31,32,33,34,35,36,37,38],"peanut allergy","immunotherapy","transdermal","microneedle","viaskin","palforzia","pediatric","adolescent","children","patch","RECRUITING","2026-06-29",{"date":42,"type":43},"2026-07-01","ACTUAL",{"date":45,"type":21},"2026-06-05",{"date":47,"type":21},"2027-12-31",{"name":49,"class":50},"Moonlight Therapeutics, Inc.","INDUSTRY",5,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":18,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100594173","phase-2-efficacy-of-tezepelumab-in-peanut-oral-immunotherapy-100594173","NCT07015996","Efficacy of Tezepelumab in Peanut Oral Immunotherapy","Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Trial","ZENITH","Inclusion Criteria:\n\n1. Participant and\u002For parent\u002Flegal guardian must be able to understand and provide informed consent (parental permission and informed assent of minor, if applicable).\n2. Age 12 to 55 years inclusive with a personal history of an allergic reaction to peanut ingestion\n3. A positive reaction at or below ingestion of 100 mg of peanut protein in a single dose (≤ 144 mg cumulative dose) during the Screening DBPCFC\n4. A negative challenge to the placebo (oat) during the Screening DBPCFC\n5. Sensitization to peanut as evidenced by either one of the following:\n\n   1. positive sIgE to Ara h2 ≥ 0.35 kU\u002FL by ImmunoCAPTM testing, or\n   2. wheal ≥ 3 mm on skin prick test to peanut extract compared to a negative control\n6. Female participants of childbearing potential must have a negative pregnancy test upon study entry\n7. Female participants with reproductive potential must agree to use an FDA approved method of contraception for the duration of the study\n8. Willing and able to comply with the study protocol requirements\n9. Participants with other food allergies must agree to continue avoidance of these food items from their diet to avoid confounding the safety and efficacy data of the study\n\nExclusion Criteria:\n\n1. Currently in build-up phase of aeroallergen immunotherapy\n2. Current food allergen immunotherapy or use of any food allergen immunotherapy within the past 12 months\n3. Pregnant, planning a pregnancy during the study, or breast-feeding\n4. History of intolerance, hypersensitivity, or allergic reactions to tezepelumab, or the inactive ingredients (excipients) of tezepelumab, other IgG biologics, or rescue medications and their excipients\n5. Allergy to oat (participant reported)\n6. History of severe systemic allergic reaction to peanut with symptoms including the need for mechanical ventilation and\u002For severe hypotension requiring intensive care unit admission\n7. Asthma requiring high dose inhaled corticosteroid therapy for control (2007 NHLBI Criteria Steps 5 or 6 in adults and adolescents)\n8. History of a life-threatening asthma attack within 12 months prior to screening (e.g., requiring an ICU admission or intubation with mechanical ventilation), need for oral corticosteroids for asthma management within the last 6 months, or current Asthma Control Test score less than 19 at screening\n9. History of ischemic cardiovascular disease or other cardiac disease, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study\n10. History of eosinophilic gastrointestinal disease at screening\n11. History of disease affecting the immune system such as autoimmune disease (e.g., systemic lupus erythematosus), immune complex disease (e.g., serum sickness), or immunodeficiency, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study\n12. History of malignancy of any type, excluding basal cell and squamous cell cancers of the skin that only required surgical excision or in situ carcinoma of the cervix study provided that curative therapy was completed at least 12 months prior to screening\n13. Current known helminth infection\n14. Positive QuantiFERON - TB Gold test or TB Gold Plus, or T-SPOT® TB test unless the potential participant has been treated with appropriate chemoprophylaxis. In the case of an indeterminate or borderline Interferon Gamma Release Assay (IGRA), an IGRA may be repeated.\n15. Any of the following:\n\n    1. HIV\n    2. Current or prior infection with hepatitis B virus (HBV)\n    3. Current or prior infection with hepatitis C virus (HCV), except adequately treated HCV with sustained virologic response ≥ 12 weeks.\n16. Active liver disease, defined as either:\n\n    1. AST, ALT, and\u002For Alk phos \\>2x ULN, or\n    2. other active liver disease which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study\n17. Any of the following:\n\n    1. Current use of beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers\n    2. Received any investigational product within the past 4 months or 5 half-lives (whichever is longer) prior to screening\n    3. Received systemic corticosteroids within 14 days prior to screening\n    4. Receipt of immunoglobulin or other blood product within 30 days prior to screening\n    5. Receipt of live attenuated vaccine within 30 days prior to screening\n    6. Use of an immunosuppressant or immunomodulating drug within 30 days prior to screening\n    7. Use of biologics targeting the human immune system within the past 12 months prior to screening\n    8. Use of any herbal medications, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study\n18. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study","12 Years",{"count":62,"type":21},62,[64],"PHASE2","The proposed study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab and peanut Oral Immunotherapy (OIT) for the treatment of peanut allergy. Study participation is divided into 3 periods: (i) a monotherapy period comprised of injections of either Tezepelumab or placebo from week 0 to week 8, (ii) followed by a combination therapy period comprised of 56 weeks during which peanut OIT is built up and maintained, and (iii) a treatment withdrawal period comprised of 12 weeks. This study will enroll 62 peanut-allergic individuals from 12 to 55 years of age who experience dose-limiting symptoms to \\\u003C=100 mg of peanut protein in a single dose (\\\u003C= 144 mg cumulative dose) as assessed by DBPCFC.\n\nThe primary objective is to determine whether 56 weeks of tezepelumab plus peanut OIT as compared to 56 weeks of placebo plus peanut OIT induces sustained unresponsiveness to peanut 12 weeks after stopping combination therapy.",[27],[68,69,70],"Tezepelumab","Peanut","Oral Immunotherapy","2026-06-24",{"date":73,"type":43},"2026-06-26",{"date":75,"type":21},"2026-07-15",{"date":77,"type":21},"2028-09-16",{"name":79,"class":80},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",10,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":18,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":51},"100619791","phase-1-ukk-0018-as-an-immunotherapeutic-for-treatment-of-peanut-allergies-100619791","NCT07349212","UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies","A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals","UKK-0018","Inclusion Criteria:\n\n* Adults 18-55 years old\n* documented history of physician-diagnosed peanut allergy\n* positive skin prick test (SPT)\n* screening DBPCFC peanut protein\n* contraception use should be consistent with local regulations\n* capable of providing signed written informed consent\n\nExclusion Criteria:\n\n* asthma based on NHLBI\n* uncontrolled cardiovascular disease\n* chronic disease history\n* exacerbation of dermatological conditions\n* life threatening episodes of anaphylaxis\n* active infections\n* poor physical or blood chemistry\n* immunodeficiency, bleeding disorders, malignancies\n* hypersensitivities to epinephrine, inactive ingredients in therapy\n* pregnant or breast feeding","18 Years",{"count":20,"type":21},[24,64],"This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.",[95,27],"Peanut-Induced Anaphylaxis",[97,29],"peanut","2026-06-22",{"date":100,"type":43},"2026-06-25",{"date":102,"type":43},"2026-02-18",{"date":104,"type":21},"2027-11-01",{"name":106,"class":50},"Ukko Inc",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100593244","phase-3-safety-study-of-viaskin-peanut-patch-in-peanut-allergic-children-1-through-3-years-of-age-comfort-toddlers-100593244","NCT07003919","Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)","A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With DBV712 250 mcg in 1-through 3-year-old Children With Peanut Allergy","Key Inclusion Criteria:\n\n* Aged 1 through 3 years at Visit 1 (screening).\n* Physician-diagnosed peanut allergy and following a strict peanut-free diet\n* Peanut-specific IgE \\> 0.7 kUA\u002FL.\n* A positive peanut SPT with the largest wheal diameter of ≥ 6 mm at Visit 1 (screening).\n* An ED ≤ 300 mg peanut protein at screening double-blind placebo-controlled food challenge (DBPCFC).\n\nKey Exclusion Criteria:\n\n* Peanut allergic subjects presenting a medical history of severe anaphylaxis to peanut.\n* Severe generalized dermatologic disease involving the proposed treatment application area (interscapular region).\n* Current immunotherapy for any allergen (including food allergy, allergic rhinitis and\u002For insect allergy).\n* History of any immunotherapy for peanut allergy, including Epicutaneous immunotherapy (EPIT), oral immunotherapy (OIT), sublingual immunotherapy (SLIT).\n* Treatment with any monoclonal antibody or biologic immunomodulatory therapy within 6 months prior to Visit 1.\n* Uncontrolled persistent asthma.","1 Year","3 Years",{"count":117,"type":21},480,[119],"PHASE3","The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.",[122,27],"Allergy",[124,125,126,127,128,129,130,27,131,132,133],"Peanut hypersensitivity","Epicutaneous Immunotherapy (EPIT)","Epicutaneous","Immunotherapy","Viaskin","Nut and Peanut Hypersensitivity","Food Hypersensitivity","Food Allergy","Nut and Peanut Allergy","Safety Study","2026-06-17",{"date":136,"type":43},"2026-06-18",{"date":138,"type":43},"2025-06-24",{"date":140,"type":21},"2028-05",{"name":142,"class":50},"DBV Technologies",91,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":171},"100535770","investigating-modified-protocols-of-oral-immunotherapy-to-validate-efficacy-and-safety-100535770","NCT06256146","Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety","IMPROVES","Inclusion Criteria:\n\n* A history suggestive of immediate allergy to the food. A convincing clinical history of an IgE mediated reaction to a specific food will be defined as a minimum of 2 mild signs\u002Fsymptoms or 1 moderate or 1 severe sign\u002Fsymptom that was likely IgE mediated and occurred within 120 minutes after ingestion or contact\n* The presence of at least one of the following confirmatory tests:\n\n  * Positive SPT to the culprit food allergen (weal diameter 3 mm larger than that of the normal saline control). The allergens used will be commercial extracts of the foods (Omega Labs, Toronto, Ontario).\n  * Detection of serum specific IgE (\\>0.35 kU\u002FL) to the culprit food or any of its proteins, measured by fluorescence enzyme immunoassay (Phadia, CAP System, Uppsala, Sweden).\n\nExclusion Criteria:\n\n* Patients who have uncontrolled respiratory disease (asthma, cystic fibrosis, etc.)\n* Patients who present with intercurrent disease active at the time of starting desensitization.\n* Non IgE mediated or non-immunological adverse reactions to milk or peanuts.\n* Malignant or immunopathological diseases and\u002For severe primary or secondary immune deficiencies.\n* Patients receiving oral immunosuppressor therapy.\n* Patients receiving β-blockers (including topical formulations), or who receive daily doses of NSAIDs, aspirin or ACE inhibitors for cardiac issues.\n* Associated diseases contraindicating the use of epinephrine: cardiovascular disease, severe hypertension or hypotension.\n* Patients diagnosed with eosinophilic gastrointestinal disorders, including patients with a history of antacid use for reflux related to food impaction or with a history of esophageal spasm.\n* Patients already tolerating processed\u002Fcooked forms of the food (e.g.,baked goods with milk).","2 Years","40 Years",{"count":154,"type":21},360,[156],"NA","Protocols for Oral Immunotherapy (OIT) for the main food allergens have been recently incorporated in clinical practice for food allergies and their clinical benefits have been acknowledged in European and Canadian official guidelines. There has been some reluctance in both clinicians and patients to implement these therapies, primarily because of the risk of allergic reactions during the desensitization process. This study will investigate if protocols using low doses of a food allergen or processed versions of the allergen can be both effective in conferring desensitization while inducing fewer allergic symptoms during the desensitization process.",[27,159,160],"Milk Allergy, Cow's","Egg Allergy","2026-05-01",{"date":163,"type":43},"2026-05-07",{"date":165,"type":43},"2022-03-01",{"date":167,"type":21},"2030-02-28",{"name":169,"class":170},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":179,"sex":16,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":171},"100601989","phase-1-study-of-enp-501-in-peanut-allergic-and-non-allergic-participants-100601989","NCT07117669","Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants","A Phase 1\u002F2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ENP-501 in Non-Peanut Allergic Participants and Participants With a Known Peanut Allergy","Inclusion Criteria:\n\nPart 1:\n\n* 14-50 years of age (inclusive)\n* Otherwise medically healthy and able to participate in the study\n* Able to perform spirometry testing in accordance with the American Thoracic Society (ATS) guidelines (2019)\n* All women of child-bearing potential, agree to either abstain from sexual activity or agree to use an adequate method of contraception for the duration of the study and for 30 days after the last dose of investigational product\n* Signed and dated written informed consent from the participant and\u002For parent or guardian\n* Signed and dated assent from participant under 18 in accordance with local IRB regulations\n* Willing and able to avoid peanut and peanut contaminants for the duration of the trial\n\nPart 1 Cohort 1 only (NPA Participants)\n\n* No known clinical history of peanut allergy with regular exposure to peanuts in daily life, i.e ingests peanuts without symptoms\n* Negative Skin Prick Test (SPT) (wheal diameter of \\\u003C3 mm) to peanut\n\nPart 1 Cohort 2 only (PA Participants)\n\n* A documented clinical history of peanut allergy, which includes the development of symptoms (e.g., urticaria, flushing, rhinorrhea and sneezing, throat tightness or hoarseness, wheezing, vomiting) verified by a physician\n* At least two of the three following requirements:\n\n  1. Positive Skin Prick Test (SPT) (wheal diameter of ≥ 8 mm) to peanut\n  2. An elevated serum peanut specific IgE level ≥ 7 kUA\u002FL (ImmunoCAP®)\n  3. An Ara-h2 IgE level of ≥ 2 kUA\u002FL (ImmunoCAP®)\n\nPart 2:\n\n* 14 to 50 years of age (inclusive)\n* A documented clinical history of peanut allergy, which includes the development of symptoms (e.g., urticaria, flushing, rhinorrhea and sneezing, throat tightness or hoarseness, wheezing, vomiting) verified by a physician\n* At least two of the three following requirements at screening:\n\n  1. Positive SPT (wheal diameter of ≥ 3 mm) to peanut\n  2. Serum peanut-specific IgE level ≥ 0.7 kUA\u002FL (ImmunoCAP®)\n  3. An Ara-h2 IgE level of ≥ 0.5 kUA\u002FL (ImmunoCAP®) within 1 year of enrollment\n* Participant must be willing and able to complete a DBPCFC at screening and EOT (24-hours after last dose) and experience dose-limiting symptoms at or before the 300 mg challenge dose of peanut protein during a Double Blind, Placebo Controlled Food Challenge (DBPCFC) conducted in accordance with Practical Issues in Allergology, Joint United States\u002FEuropean Union Initiative (PRACTALL) guidelines\n* Otherwise medically healthy and able to participate in the study\n* Able to perform spirometry testing in accordance with the ATS guidelines (2019)\n* All women of child-bearing potential, agree to either abstain from sexual activity or agree to use an adequate method of contraception for the duration of the study and for 30 days after the last dose of investigational product\n* Signed and dated written informed consent from the participant and\u002For parent or guardian\n* Signed and dated assent from participant under 18 in accordance with local IRB regulations\n* Willing and able to avoid peanut and peanut contaminants for the duration of the trial\n\nExclusion Criteria:\n\n* History of severe anaphylactic event requiring mechanical ventilation or use of intravenous (IV) vasopressor drugs\n* Clinically significant screening electrocardiogram (ECG) abnormality or corrected QTcF \\>\u002F= 450 msec at Screening\n* FEV1 value \\\u003C 80% predicted at Screening\n* Any hospitalization in the past year for asthma, \\>1 course of oral steroids for asthma in the past 6 months, or any emergency room visit in the past 6 months for asthma\n* Poorly controlled atopic dermatitis\n* Eosinophilic gastrointestinal disease\n* Use of oral or IV corticosteroids within 30 days of Screening\n* Use of tricyclic antidepressants within 6 months of Screening\n* Inability to discontinue antihistamines for at least 5 half-lives before skin testing\n* Use of omalizumab or other immunomodulatory therapy (not including corticosteroids) or biologic therapy within one year of Screening\n* Use of any food allergen-specific or other non-traditional form of allergen immunotherapy within one year of Screening\n* Use of immunosuppressive drugs within 30 days of Screening\n* Use of ß-blockers (oral)\n* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and\u002For laboratory studies including urinalysis\n* Pregnant or breast-feeding (if female)\n* Behavioral, cognitive, or psychiatric disease that in the opinion of the Investigator affects the ability of the participant to understand and cooperate with the study protocol\n* Known allergy to inactive ingredients of investigational product (active or placebo)\n* Participation in another interventional clinical trial within 30 days of Screening or within 5 half-lives of the other IP\n* Residing at the same address as another participant in this or any peanut immunotherapy study",true,"14 Years","50 Years",{"count":183,"type":21},68,[24,64],"This is a Phase 1\u002F2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)",[27],[188],"Peanut Hypersensitivity","2026-04-23",{"date":191,"type":43},"2026-04-24",{"date":193,"type":43},"2025-12-16",{"date":195,"type":21},"2028-11",{"name":197,"class":50},"N-Fold, LLC",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":171},"100626728","phase-2-comparing-standard-and-autoclaved-peanut-oral-immunotherapy-in-people-with-peanut-allergy-100626728","NCT07439406","Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy","Oral Immunotherapy Comparing Standard and Autoclaved Peanuts in Peanut-Allergic Individuals","Inclusion Criteria:\n\n* Peanut-allergic subjects between the ages of 4 and 30 years old who satisfy all the following criteria will be included:\n\n  * A history suggestive of immediate IgE-mediated peanut allergy (more than 2 mild symptoms or more than 1 moderate or severe symptom within 120 minutes of ingestion or contact).\n  * Confirmation of peanut allergy with at least one of the following:\n  * Positive SPT to peanut (wheal equal of more than 3 mm above saline control).\n  * Serum specific IgE equal or more than 0.35 kU\u002FL to peanut or peanut components.\n  * Previous positive oral food challenge to peanut (raw, roasted or blanched) according to EAACI guidelines.\n  * Positive DBPCFC to blanched peanut at screening.\n  * Signed informed consent (parental\u002Flegal guardian consent if under 18 years old).\n\nExclusion Criteria:\n\n* • Unstable asthma or uncontrolled chronic respiratory disease.\n\n  * Active infectious or inflammatory conditions.\n  * Non-IgE-mediated or non-immunological adverse reactions to peanuts.\n  * Patients receiving immunosuppressor therapy.\n  * Patients receiving β-blockers (including topical formulations).\n  * Associated diseases contraindicating the use of epinephrine: cardiovascular disease or uncontrolled hypertension.\n  * Eosinophilic gastrointestinal disorder.\n  * Any other condition that, in the opinion of the investigators, poses excessive risk or interferes with protocol adherence.","30 Years",{"count":207,"type":21},57,[64],"Peanut allergy can cause serious and potentially life-threatening allergic reactions. Oral immunotherapy (OIT) is an investigational treatment that involves giving small, gradually increasing amounts of peanut protein to help reduce allergic sensitivity. However, OIT may cause allergic reactions during treatment.\n\nThis Phase II clinical trial will compare two forms of peanut used for oral immunotherapy: standard blanched peanuts and autoclaved peanuts (peanuts heated under high temperature and pressure to modify their proteins). Participants aged 4 to 30 years with confirmed peanut allergy will be randomly assigned to receive one of the two treatments.\n\nThe study will evaluate safety, tolerability, adherence, and the ability to tolerate a higher amount of peanut protein after 12 months of therapy. The goal is to determine whether autoclaved peanuts provide a safer and better tolerated approach to peanut oral immunotherapy.",[27],[212,213,214,29],"Autoclaved peanut","Oral immunotherapy","OIT","NOT_YET_RECRUITING","2026-02-27",{"date":218,"type":43},"2026-03-03",{"date":220,"type":21},"2026-08-01",{"date":222,"type":21},"2028-08-31",{"name":169,"class":170},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":231,"enrollmentInfo":4,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":237,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":241,"locationsCount":171},"100471888","expanded-access-protocol-of-viaskin-peanut-dbv712-in-peanut-allergic-children-100471888","NCT05424731","Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children","Viaskin® Peanut (DBV712) Compassionate Use in Peanut-allergic Children Previously Enrolled in a DBV712 Clinical Study","Inclusion Criteria:\n\n* Participation is by invitation, limited to individuals completing clinical study V712-303 (PEOPLE), previous Expanded Access Program or a DBV clinical study initiated after 31-Jan-2022\n* Male and females; ages ≥ 2 years old at Visit 1 or current or prior studies.\n* Negative urine pregnancy test for female participants of childbearing potential.\n\nExclusion Criteria:\n\n* Early withdrawal from a DBV712 clinical study.\n* History of non-compliance during the primary clinical study or unable to follow the protocol requirements.\n* Generalized dermatologic disease extending widely on the skin.\n* History of intolerance or who developed hypersensitivity to excipients of the DBV712 patches.","17 Years","EXPANDED_ACCESS","This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.",[27],[236,126,127,128],"EPIT","AVAILABLE","2026-01-14",{"date":240,"type":43},"2026-01-15",{"name":142,"class":50},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":231,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":171},"100492677","phase-2-evaluating-the-safety-and-efficacy-of-oral-encapsulated-microbiota-transplantation-therapy-in-peanut-allergic-patients-100492677","NCT05695261","Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients","A Phase II Trial to Evaluate the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients","The study will enroll 24 peanut allergic patients aged 12-17 who meet the eligibility criteria in Part A and 13 subjects aged 12-17 years who meet eligibility criteria in Part B.\n\nInclusion Criteria:\n\nMale and female young adults aged 12-17 years, who meet all the following inclusion criteria, will be enrolled in the study.\n\n1. Develop dose limiting symptoms to peanut during a DPBCFC conducted in accordance with PRACTALL (Practical Issues in Allergology, Joint United States\u002FEuropean Union Initiative) guidelines at 1 mg, 3 mg, 10 mg, 30 mg, or 100 mg peanut protein (Part A only).\n2. Has a positive SPT to peanut (≥3mm) and\u002For a positive peanut-specific IgE \\>0.35kU\u002FL (Part A only).\n3. For asthmatic patients, has a Spirometry or Peak Flow with Measurement of FEV1\\>=80% of predicted\n4. Has a negative urine hCG test if a female participant.\n5. Agrees to use an acceptable single-barrier form of birth control from enrollment through the exit DBPCFC study visit if female of childbearing potential and sexually active. An example of a single-barrier method of contraception includes condoms or oral contraceptives. Acceptable methods of birth control include implants, injectables, combined oral contraceptives, some intrauterine contraceptive devises (IUDs), sexual abstinence, a vasectomized partner, the contraceptive patch, the contraceptive ring, and condoms.\n6. Able to swallow 2 empty capsules size 00.\n7. Able to give informed assent and guardian willing to give informed consent.\n8. Willing and able to participate in the study requirements, including study visits, food challenges, serial stool collection\n9. Willing to undergo telephone or email follow-up to assess for safety and adverse events.\n10. Subject has been on maintenance peanut oral immunotherapy for at least a year (part B only).\n\nExclusion Criteria:\n\nSubjects who fall into any of the following exclusion criteria at the time of screening are not eligible for enrollment into the study.\n\n1. Patients with a history of severe anaphylaxis to any food (hypotension requiring vasopressor support, hypoxia requiring mechanical ventilation, or neurological compromise)\n2. For Part A, patients with current diagnosis of an IgE mediated reactions to food (excluding allergic reactions to peanut, tree nuts, egg and milk, provided that MTT does not contain traces of these food estimated to be above the LOAEL in 5 capsules combined, and excluding oral allergy syndrome, and excluding other foods that the MTT donor avoided)\n3. For Part B, patients with current diagnosis of an IgE mediated reactions to food (excluding allergic reactions to peanut, tree nuts, egg and milk, provided that MTT does not contain traces of tree nuts, egg and milk estimated to be above the LOAEL in 4 capsules, and excluding oral allergy syndrome, excluding the food that the patient is undergoing immunotherapy to, and excluding other foods that the MTT donor avoided).\n4. Patients with chronic illness other than controlled asthma that is mild intermittent, mild- persistent or moderate persistent, mild eczema and allergic rhinitis. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment.\n5. Recurrent or chronic infections necessitating frequent systemic (including oral) antibiotic administration.\n6. Patients on chronic systemic immunosuppressive therapies.\n7. Patients who are diagnosed with active, chronic urticaria.\n8. Patients who have received peanut oral immunotherapy within the past 6 months (Part A only).\n9. Patients who are on the up-dosing phase of aeroallergen immunotherapy or patients who have received Omalizumab or dupilumab therapy within the past 6 months.\n10. Women who are pregnant or breast feeding or planning to get pregnant during the time of the study.\n11. Sexually active female patients who refuse to use contraception from enrollment through the third DBPCFC study visit\n12. Patient with GI conditions including inflammatory bowel disease, eosinophilic esophagitis, food protein induced enterocolitis, uncontrolled reflux despite medication, uncontrolled chronic constipation despite medication, esophageal dysmotility, swallowing dysfunction, delayed gastric emptying syndromes, pill esophagitis or history of aspiration pneumonia within 3 months prior to screening.\n13. Patient with current rheumatologic conditions. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment.\n14. Patients with neutropenia \\\u003C1000 cells\u002FuL\n15. Patients participating or planning to participate in the next 6 months in interventional research trials. Exceptions can be made per PI discretion.\n16. Patients who have received systemic corticosteroids therapy for 1 week or more over the past 60 days.\n17. Patient with an allergy to Vancomycin or Neomycin or any component to the capsules.",{"count":250,"type":21},37,[64],"This is a phase II trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective for Part A is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from \\\u003C=100 mg peanut protein to 300 mg after 28 days of MTT \u002Fplacebo therapy and 4 months post therapy initiation. The primary objective for Part B is to evaluate whether MTT with antibiotic pretreatment can lead to sustained unresponsiveness (SU) defined as tolerating the same dose of peanut protein administered during a food challenge at baseline and 12 weeks after OIT cessation.",[254,27,188,95,131,255],"Allergy, Peanut","Food Allergy Peanut","2025-08-19",{"date":258,"type":43},"2025-08-24",{"date":260,"type":43},"2023-06-08",{"date":262,"type":21},"2027-03-01",{"name":264,"class":170},"Rima Rachid",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100375060","phase-1-oral-immunotherapy-for-peanut-allergic-patients-100375060","NCT04163562","Oral Immunotherapy for Peanut Allergic Patients","A Multicenter Double-blind, Randomized, Placebocontrolled Phase I\u002FII Study to Determine the Safety, Tolerability, Potential Efficacy and Dose Finding of INP20, an Oral Formulation for Treatment of Immunotherapy in Peanut-allergic Patients","Inclusion Criteria:\n\n* The presence of specific IgE to peanuts (a positive skin prick test to peanuts (diameter of wheal \\> 3.0 mm) and a positive peanut IgEs \\[CAP-FEIA\\] \\> 0.35 kUA\u002FL.\n* A history of significant clinical symptoms occurring within 60 minutes after ingesting peanuts.\n* Have a positive double-blind placebo-controlled food challenge (DBPCFC) to peanut at a cumulative dose of less than 10 grams of peanut protein.\n* Provide signed informed consent for the participation in the study.\n* Have self-injectable epinephrine available at home and be trained on its proper use.\n* Potentially fertile women must agree to be sexually inactive or to use appropriate contraceptive measures for the duration of the study and for 1 month afterward.\n\nExclusion Criteria:\n\n* History of severe anaphylaxis to peanut as defined by respiratory distress with cyanosis, hypoxemia (O2 Sat \\\u003C92%) or, in the absence of other clinical records, severe dyspnea; hypotension with or without loss of consciousness; or relaxation of sphincters.\n* Currently participating in another study using an investigational new drug.\n* Participation in any interventional study, specific oral or sublingual immunotherapy building up phase for the treatment of food allergy in the past 12 months.\n* Allergic to placebo ingredients or reacts to any dose of placebo during study entry DBPCFC.\n* Patients allergic to corn food.\n* Poor control or persistent activation of severe atopic dermatitis.\n* Moderate to severe persistent asthma.\n* Prior intubation\u002Fmechanical ventilation for asthma.\n* Currently being treated with greater than medium daily doses of inhaled corticosteroids (fluticasone \\>500 μg per day, ciclesonide \\>400 μg per day or budesonide \\>800 μg per day) or montelukast.\n* Chronic gastrointestinal diseases.\n* Primary or secondary immunodeficiency.\n* Have a severe reaction at initial DBPCFC (life-threatening anaphylaxis or reaction requiring hospitalization).\n* Chronic use of beta blockers, angiotensin converting enzyme inhibitors, or monoamine oxidase inhibitors, proton pump inhibitors, H2-bloquers, prokinetic drugs and laxatives.\n* Inability to discontinue antihistamines for 7 days before skin testing and oral food challenges (OFCs).\n* Patients diagnosed with other serious food allergies defined as those who have required intubation and\u002For ICU admission.\n* Women of childbearing potential (unless they are using highly effective methods of contraception during dosing and for at least 1 month after stopping medication), who are pregnant, planning to become pregnant, or breastfeeding.\n* Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study may also exclude a participant from the study.","65 Years",{"count":274,"type":21},50,[24,64],"Multicenter, double-blind, randomized, placebo-controlled phase I\u002FII study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral immunotherapy in peanut-allergic patients. The overall study design consists of two sequential periods of Part A and Part B.\n\nPart A is a dose escalation study in patients from 12 to 65 years old with a history of immediate hypersensitive reaction to peanut protein. Six diferent oral-dose of INP20 will be administered to 6 cohorts of patients once daily for 2 weeks.\n\nPart B is a 6-month double-blind, placebo-controlled, randomized and parallel groups study. Patients will be randomized in a 1:1:1 ratio into three (3) different treatment groups, including placebo and the two doses of peanut protein selected from Part A. They will recieve INP20 once daily for 6 months.",[27],"2025-04-29",{"date":280,"type":43},"2025-04-30",{"date":282,"type":43},"2020-03-11",{"date":284,"type":21},"2025-09",{"name":286,"class":50},"InnoUp Farma S.L.",2,{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":179,"sex":16,"minAge":115,"maxAge":231,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":171},"100490552","immune-supportive-diet-and-gut-permeability-in-allergic-children-100490552","NCT05667610","Immune-supportive Diet and Gut Permeability in Allergic Children","Effect of an Immune-supportive Diet on Gut Permeability and Allergic Symptoms in Children With Peanut and\u002For Nut Allergy","DIAMETER","Inclusion Criteria:\n\n* Children of 3 to 17 years of age with a positive open or double-blind placebo-controlled peanut or nut challenge \\\u003C 12 months to inclusion OR an obvious and objective IgE-mediated allergic reaction following the consumption of isolated peanut or nut within 1 hours, confirmed by sensitisation to peanut or nut \\\u003C 24 months to inclusion;\n* Children who are potty trained or house trained;\n* Presence of IgE to peanut ≥0.35 kilo units per liter (kU\u002Fl) or skin prick test \\> 3 mm to peanut or nut, \\\u003C 12 months prior to challenge.\n\nExclusion Criteria:\n\n* Only mild symptoms in the oral cavity to peanut or nut due to pollen food syndrome;\n* A negative peanut or nut challenge;\n* Children who are not potty trained (house trained);\n* Gastro-intestinal diseases (e.g. Morbus Crohn, coeliac disease, Colitis Ulcerosa), lactose intolerance\n* severe cow's milk allergy -because of possible traces of cow's milk in lactose in the SAT), syndromes, infectious\u002Fimmunology diseases other than atopy, or diabetes;\n* Laxative treatment, such as lactulose;\n* Not able to read or write Dutch.",{"count":297,"type":21},132,[156],"Peanut and nut allergy can be life threatening. Some patients have very low threshold levels (i.e. the amounts of peanut and nuts to which the patients react), others react to higher doses. The reasons for these differences in threshold are not well understood. Patients with peanut and nut allergy often suffer from other allergic diseases (atopic dermatitis, hay fever and asthma). A disturbed gut microbiota composition and an increased gut permeability may explain the development of allergic disease. We hypothesize that increased gut permeability is related to low threshold levels to peanuts or nuts. In addition, as it is known that nutrition can influence our gut permeability, we also hypothesize that a healthful immune-supportive diet restores gut permeability and alleviates symptoms.\n\nTherefore, the purpose of the study is to study in peanut and nut allergic children:\n\n1. the relationship between gut permeability and threshold levels to peanut or nuts;\n2. the effect of an immune-supportive diet on gut permeability, gut microbiome composition, coexisting allergic symptoms and quality of life",[27,301],"Nut Allergy",[303,304,305],"Gut permeability","Immune-supportive diet","Thresholds","2025-04-28",{"date":308,"type":43},"2025-05-01",{"date":310,"type":43},"2022-09-08",{"date":312,"type":21},"2027-06-30",{"name":314,"class":170},"Onze Lieve Vrouwe Gasthuis",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":18,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":171},"100357665","phase-1-ve416-for-treatment-of-food-allergy-100357665","NCT03936998","VE416 for Treatment of Food Allergy","VE416 and Low-dose Peanut Oral Immunotherapy for Treatment of Persistent Peanut Allergy","Inclusion Criteria:\n\n* People of all ethnic\u002Fracial\u002Fgender groups aged 12-55 years old with a documented medical history of peanut allergy.\n* Evidence of peanut-specific IgE by either: positive skin prick test to peanut (reaction wheal at least 5 mm larger than saline control) or serum peanut-specific IgE \\_5 kU\u002FL at screening visit.\n* Ara h 2 specific IgE \\>0.35 kU\u002FL at screening visit.\n* Willing to sign informed consent or whose parent or legal guardian is willing to sign the consent form (age appropriate).\n* Willing to sign the assent form, if age appropriate.\n* (For continuation into Phase II only) Allergic reaction requiring treatment at \\_ 100 mg dose of peanut protein during Entry Challenge.\n\nExclusion Criteria:\n\n* History of severe anaphylaxis as defined by hypoxia (cyanosis or SpO2 \\\u003C92% during reaction), documented hypotension (documented systolic BP \\>30% below predicted normal for sex, height, weight or from known baseline), neurological compromise (confusion, loss of consciousness), or incontinence.\n* Severe or Moderate asthma as defined using the severity criteria of the current NHLBI Guidelines for the Diagnosis and Management of Asthma (http:\u002F\u002Fwww.nhlbi.nih.gov\u002Fguidelines\u002Fasthma\u002F).\n* Poorly-controlled asthma as defined by FEV1 \\\u003C80% or any of the following symptoms: nighttime awakening \\>2 days\u002Fweek or rescue medication use \\>2 days \u002F week.\n* Diagnosis of other severe or complicating medical problems, including autoimmune or chronic immune inflammatory conditions or gastrointestinal inflammatory conditions, including Celiac Disease, Inflammatory Bowel Disease and Eosinophilic Gastrointestinal Disorders\n* Inability to cooperate with and\u002For perform oral food challenge procedures.\n* Inability to swallow size 0 capsule\n* Primary Immune Deficiency\n* Allergy to oat confirmed by skin prick testing and history\n* Current use of beta blockers, angiotensin converting enzyme inhibitors, or monoamine oxidase inhibitors\n* Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding\n* Hematocrit \\\u003C0.36 for adult females or \\\u003C0.38 for adult males Weight \\\u003C23 kg\n* Use within the past 6 months of other systemic immunomodulatory treatments including allergen immunotherapy, or use of biologics with an immune target, including omalizumab.\n* Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study may also exclude a participant from the study.",{"count":323,"type":21},60,[24,64],"This is a single-center, randomized, double-blind trial with four arms evaluating VE416 as pretreatment or concurrent treatment in comparison to low-dose peanut oral immunotherapy (PNOIT) alone.",[27],"2023-10-17",{"date":329,"type":43},"2023-10-18",{"date":331,"type":43},"2019-06-28",{"date":333,"type":21},"2024-01-01",{"name":335,"class":170},"Massachusetts General Hospital"]